Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PAX6
REST API REST API
Homo sapiens
PAX6 is differentially expressed in 225 experiments: 160 organism parts: cerebellum, lung, ... (158 more);, 143 disease states: normal, glioblastoma, ... (141 more);, 63 cell types 483 cell lines 27 compound treatments and 69 other conditions.
Synonyms AN2, AN, WAGR, D11S812E
Orthologs Pax6 (Mus musculus)   pax6a (Danio rerio)   PAX6_BOVIN (Bos taurus)   Pax6 (Rattus norvegicus)   pax6b (Danio rerio)   F6PW95_CIOIN (Ciona intestinalis)   PAX6_CHICK (Gallus gallus)   ey (Drosophila melanogaster)   toy (Drosophila melanogaster)   LOC100485335 (Xenopus laevis)   A4UHF5_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, response to wounding, regulation of transcription, DNA-dependent, cytoplasm, nuclear chromatin, intracellular, negative regulation of cell proliferation, cell fate determination, transcription, DNA-dependent, protein ubiquitination, visual perception, positive regulation of gene expression, regulation of neurogenesis, salivary gland morphogenesis, transcription from RNA polymerase II promoter, smoothened signaling pathway, glucose homeostasis, cell differentiation, positive regulation of neuroblast proliferation, sequence-specific DNA binding, axon guidance, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, eye photoreceptor cell development, regulation of gene expression, regulation of cell migration, regulation of timing of cell differentiation, ubiquitin-protein ligase activity, cell fate commitment, axonogenesis, eye development, regulation of transcription from RNA polymerase II promoter, negative regulation of epithelial cell proliferation, brain development, negative regulation of neurogenesis, positive regulation of transcription, DNA-dependent, organ morphogenesis, dorsal/ventral axis specification, central nervous system development, ubiquitin protein ligase binding, dorsal/ventral pattern formation, neuron migration, cerebral cortex regionalization, pituitary gland development, intracellular part, regulation of transcription from RNA polymerase II promoter involved in somatic motor neuron fate commitment, pallium development, forebrain development, regulation of transcription from RNA polymerase II promoter involved in spinal cord motor neuron fate specification, astrocyte differentiation, co-SMAD binding, keratinocyte differentiation, forebrain-midbrain boundary formation, lacrimal gland development, blood vessel development, negative regulation of neuron differentiation, embryonic camera-type eye morphogenesis, regulation of transcription from RNA polymerase II promoter involved in ventral spinal cord interneuron specification, camera-type eye development, neuron fate commitment, positive regulation of epithelial cell differentiation, oligodendrocyte cell fate specification, forebrain dorsal/ventral pattern formation, R-SMAD binding, lens development in camera-type eye, sequence-specific DNA binding transcription factor activity, protein localization to organelle, iris morphogenesis, signal transduction involved in regulation of gene expression, RNA polymerase II core promoter sequence-specific DNA binding, sequence-specific DNA binding RNA polymerase II transcription factor activity, HMG box domain binding, transcription regulatory region DNA binding, pancreatic A cell development, commitment of neuronal cell to specific neuron type in forebrain, cornea development in camera-type eye, anterior/posterior pattern specification, forebrain anterior/posterior pattern specification
InterPro Term Paired_box_N, Homeobox
Gene-Disease Assocation FOVEAL HYPOPLASIA AND PRESENILE CATARACT SYNDROME, ECTOPIA PUPILLAE, ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION, KERATITIS, HEREDITARY, CATARACT, AUTOSOMAL DOMINANT, PETERS ANOMALY, COLOBOMA OF OPTIC NERVE, COLOBOMA, OCULAR, OPTIC NERVE HYPOPLASIA, BILATERAL, ANIRIDIA; AN
UniProt Accession P26367, Q66SS1, B1B1I8, B1B1I9, B1B1J0, D3DQZ8, Q6VMP0, Q59GD2, E9PS79, E9PRP9, F1T0F8, E9PIX4, E9PKM0, E5LBD7
Search EB-eye ENSG00000007372
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
A549
2
E-GEOD-3202, E-GEOD-6013
BT20
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
HCC38
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-19639, E-GEOD-20081
477 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-2426, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (28 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-MEXP-2426, E-MEXP-930
CD34+ cell
1
E-MEXP-583
centroblast
1
E-GEOD-15271
plasmablast
1
E-MEXP-2360
CD4+ T cell
1
E-MTAB-24
n/a
1
E-MTAB-24
57 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-2466, E-MEXP-121, ... (42 experiments)

Factor Value U/D Experiments
mesothelioma
3
E-MTAB-62, E-MTAB-37, E-MTAB-47
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-MTAB-37
AIDS-KS, KSHV-
2
E-MEXP-66, E-MTAB-62
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
acute lymphoblastic leukemia
1
2
E-GEOD-96, E-MTAB-62, E-MTAB-37
137 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-697, E-GEOD-5824, E-MEXP-2590, ... (17 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-5824, E-GEOD-412, E-GEOD-20719, E-GEOD-697
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
vanadium pentoxide
1
E-GEOD-5339
U0126
1
E-GEOD-697
hydrogen peroxide
1
E-GEOD-5339
NaOH
1
E-MEXP-2590
21 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
77
1
1
E-GEOD-3494
84
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-GEOD-2034, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-563

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, E-TABM-321, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-MEXP-1103

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-GEOD-2466, E-GEOD-1926, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-1309, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-3026

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-1561, E-GEOD-4922

Processing time: 0.288 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM